Boston, Massachusetts 02215


Purpose:

This is an open-label, single arm, dose escalation study in patients with advanced cancers.


Study summary:

This is an open-label, single arm, dose escalation study in patients with advanced cancers. Treatment will be administered on an outpatient basis.


Criteria:

Inclusion Criteria: - Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective - 18 years or older - ECOG performance status 0-1 - Life expectancy ≥ 3 months - Evaluable disease - Adequate organ functions - 4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities - At least 4 weeks from major surgery - Agree to practice effective contraception - Agree to follow protocol required evaluations - Ability to understand and willingness to sign the informed consent form Exclusion Criteria: - Previously untreated CNS metastasis or progressive CNS metastasis - Currently receiving radiotherapy, biological therapy, or any other investigational agents - Uncontrolled intercurrent illness - Pregnant or lactating women - Known to be HIV-positive - Known active hepatitis B and/or hepatitis C infection


NCT ID:

NCT02552953


Primary Contact:

Principal Investigator
Geoffrey Shapiro, MD
Dana-Farber Cancer Institute

Judy Chiao, MD
Phone: 908-517-7330


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Geoffrey Shapiro, MD

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.